BCL2 and Familial prostate cancer: Further work has shown that miR-15a and miR-16-1 act as tumor suppressors and when decreased lead to increased levels of BCL2, CCNDI, and WNT3A in prostate cancer, increased BCL2 in Chronic Lymphocytic Leukemia, and increased IGSF4 in leukemia [44–46].